产品说明
包装
5, 25 mg in glass bottle
生化/生理作用
Cholecystokinin is expressed in the gastrointestinal tract and the central nervous system. Cholecystokinin receptor type 2 (CCK2) is a GPCR that is highly expressed in brain and spinal cord. CCK2 is implicated in many brain processes, including mood, anxiety, and pain, through its modulation of GABA neurotransmission.
LY225910 is a potent, selective CCK2 antagonist. LY225910 blocks agonism of CCK2 by CCK-8S, the peptide agonist. LY225910 has been measured in multiple systems, including GABA efflux from cortical cultures, depolarization of spinal cord neurons (via potassium conductance), modulation of excitatory postsynaptic potentials (EPSPs) in nucleus accumbens slices, and enhancement of morphine analgesia.
特点和优势
This compound is featured on the Cholecystokinin and Gastrin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
基本信息
经验(实验)分子式 | C27H24BrN3O2 |
分子量 | 502.40 |
MDL编号 | MFCD00907856 |
PubChem化学物质编号 | 329817399 |
NACRES | NA.77 |
产品性质
质量水平 | 100 |
测定 | ≥98% (HPLC) |
形式 | powder |
颜色 | off-white |
溶解性 | DMSO: >20 mg/mL |
创始人 | Eli Lilly |
储存温度 | 2-8℃ |
SMILES string | CC(C)Oc1cccc(c1)N2C(CCc3c[nH]c4ccc(Br)cc34)=Nc5ccccc5C2=O |
InChI | 1S/C27H24BrN3O2/c1-17(2)33-21-7-5-6-20(15-21)31-26(30-25-9-4-3-8-22(25)27(31)32)13-10-18-16-29-24-12-11-19(28)14-23(18)24/h3-9,11-12,14-17,29H,10,13H2,1-2H3 |
InChI key | KUECXUACQOYKNB-UHFFFAOYSA-N |
安全信息
象形图 | |
警示用语: | Danger |
危险声明 | H301 - H413 |
预防措施声明 | P273 - P301 + P310 + P330 |
危险分类 | Acute Tox. 3 Oral - Aquatic Chronic 4 |
储存分类代码 | 11 - Combustible Solids |
WGK | WGK 3 |
闪点(F) | 638.6 - 762.1 °F |
闪点(C) | 337 - 405.6 ℃ |
Sigma-Aldrich